Table 1: Summary of Angiotensin-converting Enzyme Inhibitor and/or Beta-blocker in the Primary Prevention of Cardiotoxicity Before Chemotherapy.

Author and year	Medication	Chemotherapy	Patients (n)	Follow-up (months)	Results
Kalay et al. 2006[52]	Carvedilol versus placebo	Anthracycline	50	6	Placebo: LVEF Δ −16% Carvedilol: LVEF Δ −1.5%
Georgakapoulos et al. 2010[53]	Metoprolol versus enalapril versus placebo	Anthracycline	125	31	Metoprolol: LVEF Δ −3.7%* Enalapril: LVEF Δ −2% Placebo: LVEF Δ −1.4%
Bosch et al. 2013[40]	Enalapril + carvedilol versus placebo	Anthracycline	90	6	ACEI + BB: LVEF Δ 0% Placebo: LVEF Δ −11%
Akpek et al. 2014[42]	Spironolactone versus placebo	Anthracycline	83	6	Spironolactone: LVEF Δ −1.5%* Placebo: LVEF Δ −11%*
Gulati et al. 2016[41]	Candesartan versus metoprolol versus placebo	Anthracycline	130	3-12	Candesartan: LVEF Δ −0.8%* Metoprolol: LVEF Δ −0.6% Placebo: LVEF −2.6%
Boekhout et al. 2016[44]	Candesartan versus placebo	Trastuzumab	206	24	Candesartan : LVEF Δ −0% Placebo : LVEF Δ −1.5%
Pituskin et al. 2017[45]	Perindopril versus bisoprolol versus placebo	Trastuzumab	94	12	Perindopril: LVEF Δ −3% Bisoprolol: LVEF Δ −1%* Placebo: LVEF Δ −5% No effect on remodelling
Avila et al. 2018[43]	Carvedilol versus placebo	Anthracycline	200	6	Carvedilol : LVEF Δ −1.4% Placebo : LVEF Δ −2%

*p<0.05. Δ: change from baseline LVEF; ACEI = angiotensin-converting enzyme inhibitor; BB = beta-blocker; LVEF = left ventricular ejection fraction.